Czech/SlovakiaCzech RepublicSlovakia

National platform to boost industrial biotechnology

16.07.2008

Brno – Czech biotechnologists and EU industry experts have worked out an action plan to improve the development of industrial biotechnology in the Czech Republic. The recommendations are based on three SWOT analyses (R&D, Innovation, and Policy) that monitor the current development stage of industrial biotechnology worked out at a two day roundtable that brought together Czech biotech experts with representatives from EuropaBio, SusChem, the EU-tech platform for sustainable chemistry, and the European Commission in Brno.

Enabling better tech transfer

“The Czech Republic had a great past in traditional biotechnology – in fermentation, continuous culture, or biotransformations. And it pioneered antibiotic production,” summarised Dr. Peter Sebo, biotechnologist at the Czech Academy of Sciences in Prague. “But currently, there are several bottlenecks that hamper the development of modern biotechnology.” Only four out of 42 modern biotech companies (Lonza, Baxter, Comtipor, ExBio) located in the Czech Republic are currently active in industrial biotech. Sebo estimates the industry in the Czech Republic as a whole employs about 2,000 staff and has turnover of roughly EUR200m per year, but added that there is limited R&D in advanced biotech, almost no biotech IP and thus no venture capital available. Nevertheless, he remained optimistic about the future. An Institute of Biotechnology was founded this January, while a biotech and biomed research centre called BIOCEV, which by 2012 will provide labs for 450 researchers and 150 students, is being built up in Prague. Last but not least, the government has established long term funding schemes for biotechnology. “Currently we have more funding than biotech people,” said Sebo.
On a national scale, the experts called for a specific funding program for white biotech that links national participants from industry and research, as well as for the launch of an awareness campaign for communicating the advantages of White Biotech to politicians and the public. They also re­commended improving technology transfer from research to industry, and educational programs to address the lack of managerial skills among researchers. Finally, they concluded that the construction of an open production plant would give Czech biotech companies the opportunity to test large-scale production without having to build costly production facilities on their own.
At the European level, they asked for a harmonisation of IP rights, additional funding for basic research projects, less bureaucracy, and the establishment of a European seed funding programme.
“The meeting has helped to better inform the Commission about industrial biotech, and map the possibility of further financial support tailored to the Czech specific situation,” said Michal Kostka, Deputy Director of the South Moravian Innovation Centre. The round table was the first in a series of meetings in which SusChem will be assessing White Biotech activities in eight Eastern EU member states.


Czech/SlovakiaCzech RepublicSlovakia

11.07.2007

Prague/Foster City – An oligonucleotide analogon, originally developed at the Institute of Organic Chemistry and Biochemistry (IOCB) at the Czech Academy of Sciences in Prague, has entered clinical testing as treatment for...

Czech/SlovakiaCzech RepublicSlovakia

17.05.2007

Prague/Leuven – The Czech Republic is lagging behind in applying the ten year-old European convention on Human rights and biomedicine, according to a new report from EuroGentest, an EU-funded Network of Excellence, which assesses...

Czech/SlovakiaCzech RepublicSlovakia

21.11.2006

BIOTEC 2006, the first international biotechnology conference and exhibition in Eastern Europe, held at the end of October, staged the official inauguration ceremony of the International Clinical Research Center (ICRC). The...

Czech/SlovakiaCzech RepublicSlovakia

16.09.2006

In order to keep track of developments and to promote network-creation, for both domestic-domestic and domestic-foreign cooperations the South Moravian Innovation Centre, Brno, has conducted the Czech Republic’s first...

Czech/SlovakiaCzech RepublicSlovakia

21.07.2006

Bratislava – In late-April, the Slovak government authorized field trials with genetically modified MON 810 maize at three undisclosed locations. The total area of the field trials is approximately 30 hectares. Although Slovakia...

Czech/SlovakiaCzech RepublicSlovakia

21.07.2006

Pruhonice – Biomass production is a promising alternative for the Czech Republic’s agricultural sector. Biomass could cover the annual domestic bio-energy demand of 250 PJ (predicted for 2030), and could be exported as bio-fuels...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2006

Prague - The French pharma giant Sanofi-Aventis S.A. strengthened its generics business in Central and Eastern Europe (CEE) with a participation in the Czech generics producer Zentiva a.s. According to Sanofi-Aventis, the company...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2006

Brno - The International Clinical Research Center (ICRC) in Brno, will collaborate with the renowned Mayo Clinic in Rochester, MN, to establish a clinical and research education center that meets the challenges of 21st-century...

Czech/SlovakiaCzech RepublicSlovakia

17.03.2006

Humpolec - A product derived from genetically modified potatos with altered starch composition poses no threat to human health, according to a European Food Safety Authority (EFSA) panel ruling.BASF Plant Science's GM potato,...

Czech/SlovakiaCzech RepublicSlovakia

17.03.2006

Brno - Spinning out a company in the Czech Republic is far from common. That has not stopped Jiri Damborsky, who led a protein engineering group at Masaryk University, Brno, from founding his own company, Enantis. His firm will...

Displaying results 31 to 40 out of 70

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/3/article/national-platform-to-boost-industrial-biotechnology.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.23 EUR6.03%
  • VITA 343.96 EUR4.49%
  • WILEX2.36 EUR4.42%

FLOP

  • CYTOS0.26 CHF-3.70%
  • MOLOGEN7.10 EUR-2.74%
  • ADDEX4.00 CHF-1.72%

TOP

  • SANTHERA82.95 CHF19.7%
  • MAGFORCE6.50 EUR10.2%
  • LONZA101.10 CHF7.1%

FLOP

  • MOLOGEN7.10 EUR-24.5%
  • WILEX2.36 EUR-24.4%
  • 4SC1.23 EUR-15.2%

TOP

  • SANTHERA82.95 CHF3850.0%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR198.8%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.65 EUR-67.7%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 21.08.2014


Current issue

All issues

Product of the week

Products